INS and type 2 diabetes mellitus: Most participants had type 2 diabetes (85.6%), and were taking oral hypoglycaemic drugs (84.7%) rather than insulin or insulin plus oral hypoglycaemic drugs (14.4%), reflecting the distribution of type 1 and type 2 diabetes patients in the trial population (Table 1).